Dr. Larwood has tirelessly advanced an important antifungal drug to human-ready. Eradicating a rare disease, Valley Fever, in the anti-infective space is challenging to support but this superior drug will save many lives and alleviate suffering for tens of thousands. He improved the formulation to increase efficacy 30-fold, now finalizing preparation for final pre-human testing. Our group is ready to drive this to commercialization quickly with focused trials in a desperate patient population. Dr. Larwood invented his two later-commercial molecules before age 30. In his early PhD studies he was the first to make PEGylated lipids, later crucial in pharmaceuticals including the mRNA vaccine. His law degree took him into patent law at Apple and a first successful startup, then to his second startup as General Counsel, taking Verisity public for four years to a successful sale. He completed a dual MBA in time for VFS's first STTR Grant award of ~ $1M. He was Co-PI for another $6M NIH support, then found support to test his new formulations. He completed his 2024 UCSF PhD in AI-focused antimicrobial peptide design while running major animal studies for Valley Fever Solutions.